Galderma backs new evidence for Sculptra and Restylane in fast-evolving patient demand segments
Read how Galderma’s new interim data could influence aesthetic treatment planning in menopause and GLP-1-related volume loss.
Pharma & Biotech
Pharma & Biotech
Can AbbVie’s Juvéderm strategy turn subtle aesthetics into the next growth engine for fillers
AbbVie is repositioning Juvéderm for the “undetectable” aesthetics era. Read what this means for injectables, clinicians, and market competition.
Pharma & Biotech
How Galderma’s Wake Up To Restylane campaign reflects evolving aesthetics patient preferences
Explore how Galderma’s Wake Up To Restylane strategy and new IMCAS data could reshape aesthetic practice and hyaluronic acid filler adoption.
Pharma & Biotech
How Biocorneum’s new bruise kit reflects a wider shift in aesthetic medicine aftercare
Explore how Biocorneum’s dual-action bruise care system could reshape post-procedure recovery in aesthetic medicine. Read the strategic analysis now.